A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease.

ABSTRACT:

Background

A clinical decision support tool (CDST) has been validated for predicting treatment effectiveness of vedolizumab (VDZ) in Crohn's disease.

Aim

To assess the utility of this CDST for predicting exposure-efficacy and disease outcomes.

Methods

Using data from three independent datasets (GEMINI, GETAID and VICTORY), we assessed clinical remission rates and measured VDZ exposure, rapidity of onset of action, response to dose optimisation and progression to surgery by CDST-defined response groups (low, intermediate and high).

Results

A linear relationship existed between CDST-defined groups, measured VDZ exposure, rapidity of onset of action and efficacy in GEMINI through week 52 (P < 0.001 at all time points across three CDST-defined groups). In GETAID, C

SUBMITTER: Dulai PS 

PROVIDER: S-EPMC7028036 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature